Save the Date

OncologyEducation is proud to feature Dr. Caroline Robert discussing the Management of Melanoma Patients in the Metastatic and Adjuvant Setting.
This live educational program will be offered in Toronto, ON and Montréal, QC.

Venue and registration information will be available soon.

Learning Objectives:

  1. Management of patients with metastatic melanoma in terms of treatment strategy and adverse events
  2. New results in the adjuvant setting
  3. Mechanisms of resistance
  4. Potential predictive biomarkers and future directions

Target Audience: 

Medical oncologists, pharmacists, nurses treating melanoma patients. 

About the Speaker: 

Dr Marc Peeters

Dr. Caroline Robert, M.D., Ph.D.

Dr. Robert is the Head of the Dermatology Service at Gustave Roussy Cancer Campus and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. She trained at the Paris V University, France and completed a research fellowship at Harvard, Brigham & Women's hospital in Cancer Immunology and Immunotherapy. She chairs the Melanoma group of the European Organization for the Research and Treatment of Cancer (EORTC) and is board member for the European Association of Onco-Dermatology (EADO), the European Society of Medical Oncology (ESMO), the European Association of Dermato-Venereology (EADV) the French society of Dermatology and Venereology (SFD), the American Society of Oncology (ASCO) and the American Association of Clinical Research (AACR). Her main focuses of interest are clinical and translational Research on Melanoma: immunotherapy and targeted therapy, as well as the study of the cutaneous adverse events of anticancer agents. She is national and international coordinator of many clinical trials of targeted therapy and immunotherapy for melanoma patients, from phase I to III. She has authored more than 240 articles in peer-reviewed scientific journals, including a number of publications on new treatments for metastatic melanoma

Her recent work has focused on identification of new biomarkers for immunotherapy and targeted therapies of patients with melanoma.

This program was made possible by the unrestricted sponsorship support from Merck. 

Other Information

For more information, please send requests to

Oncology Clinical News

Powered by OBR Oncology